Tralokinumab is effective and safe for the treatment of patients with moderate to severe AD through 6 total years of treatment.

A new vaccine from companies Pfizer and Valneva meant to prevent Lyme disease may be one step closer to approval.

Patients with dermatomyositis in the US experience substantial variability in treatment, high glucocorticoid exposure, and significant healthcare utilization.

Acne is a common and clinically relevant adverse event among patients with IBD receiving JAK inhibitors. Acne occurs in 8.6% of individuals with inflammatory bowel diseases (IBD) who are receiving ...

The FDA accepts a New Drug Application for bezuclastinib to treat nonadvanced systemic mastocytosis based on positive data from the SUMMIT trial.

Nicotinamide supplementation has shown promising effectiveness in melanoma prevention, according to poster results from the ...

Posters presented at the 2026 AAD Annual Meeting examined bimekizumab for hidradenitis suppurative across various subgroups ...

Hand eczema in patients with AD is independently associated with worse QOL measures, with increasing burden seen with increasing hand eczema severity.

Patients with acne vulgaris who received systemic therapies had greater rates of treatment adherence and satisfaction than with topical therapies.

More than half of individuals with mpox reported persistent physical and psychosocial sequelae 11 to 18 months after acute infection.

Patients with atopic dermatitis who receive treatment with dupilumab may be at an increased risk for new-onset vitiligo.

Cardinal Health recalled some of its Webcol Large Alcohol Prep Pads as they may contain the bacteria Paenibacillus phoenicis.